Marie Goepp

Marie Goepp

Auto-generated profile, based on publicly available information

Marie Goepp

Centre for Inflammation Research, Queen’s Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
SCSiobhan Crittenden
Siobhan Crittenden
MGMarie Goepp
Marie Goepp
JPJolinda Pollock
Jolinda Pollock
CRCalum T Robb
Calum T Robb
DSDanielle J Smyth
Danielle J Smyth
CYChengcan Yao
Chengcan Yao
PGE 2 inhibits T regs and promotes intestinal inflammation through actions on mononuclear phagocytes and the gut microbiota.

23 July 2020 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
CRCalum T. Robb
Calum T. Robb
MGMarie Goepp
Marie Goepp
ARAdriano G. Rossi
Adriano G. Rossi
CYChengcan Yao
Chengcan Yao
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the cause of the novel coronavirus disease 2019 (COVID‐19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine or efficient treatment strategies against COVID‐19. Non‐steroidal anti‐inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain, and inflammation (common symptoms of COVID‐19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxyganase enzymes. PGs can exert either proinflammatory or anti‐inflammatory effects depending on the inflammatory scenario. In this review, we survey the potential roles that NSAIDs and PGs may play during SARS‐CoV‐2 infection and the development and progression of COVID‐19.Linked Articles: This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc

17 June 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAApostol Apostolov
Apostol Apostolov
ILIsma Litim-Mecheri
Isma Litim-Mecheri
AOAttila Oravecz
Attila Oravecz
MGMarie Goepp
Marie Goepp
PKPeggy Kirstetter
Peggy Kirstetter
PKPhilippe Kastner
Philippe Kastner
The Ikaros transcription factor is a tumor suppressor that is also important for lymphocyte development. How post-translational modifications influence Ikaros function remains partially understood. We show that Ikaros undergoes sumoylation in developing T cells that correspond to mono-, bi- or poly-sumoylation by SUMO1 and/or SUMO2/3 on three lysine residues (K58, K240 and K425). Sumoylation occurs in the nucleus and requires DNA binding by Ikaros. Sumoylated Ikaros is less effective than unsumoylated forms at inhibiting the expansion of murine leukemic cells, and Ikaros sumoylation is abundant in human B-cell acute lymphoblastic leukemic cells, but not in healthy peripheral blood leukocytes. Our results suggest that sumoylation may be important in modulating the tumor suppressor function of Ikaros.

29 May 2020 in Scientific Reports
Verified
Journal Article
Open access
DGDelphine Le Guennec
Delphine Le Guennec
VHVictor Hatte
Victor Hatte
MFMarie-Chantal Farges
Marie-Chantal Farges
SRStéphanie Rougé
Stéphanie Rougé
MGMarie Goepp
Marie Goepp
ARADRIEN ROSSARY
ADRIEN ROSSARY
Accumulative evidence links breast cancer development to excess weight and obesity. During obesity, dysregulations of adipose tissue induce an increase in pro-inflammatory adipokine secretions, such as leptin and oestrogen secretions. Furthermore, a raise in oxidative stress, along with a decrease in antioxidant capacity, induces and maintains chronic inflammation, which creates a permissive environment for cancer development. Physical activity is recommended as a non-pharmacological therapy in both obese and cancer situations. Physical activity is associated with a moderation of acute inflammation, higher antioxidant defences and adipokine regulation, linked to a decrease of tumour-cell proliferation. However, the biological mechanisms underlying the relationship between oxidative stress, low-grade inflammation, carcinogenesis, obesity and physical activity are poorly understood. Our study is based on old, ovariectomised mice (C57BL/6J mice, 33 weeks old), fed with a high fat diet which increases adipose tissue favouring overweight and obesity, and housed in either an enriched environment, promoting physical activity and social interactions, or a standard environment constituting close to sedentary conditions. Our model of mammary carcinogenesis allowed for the exploration of tissue secretions and signalling pathway activation as well as the oxidative status in tumours to clarify the mechanisms involved in a multiple factorial analysis of the data set. The multiple factorial analysis demonstrated that the most important variables linked to moderate, spontaneous physical activity were the increase in growth factor (epithelial growth factor (EGF), hepatocyte growth factor (HGF)) and the activation of the signalling pathways (STAT3, c-jun n-terminal kinases (JNK), EKR1/2, nuclear factor-kappa B (NF-κB)) in the gastrocnemius (G). In inguinal adipose tissue, the NF-κB inflammation pathway was activated, increasing the IL-6 content. The adiponectin plasma (P) level increased and presented an inverse correlation with tumour oxidative status. Altogether, these results demonstrated that spontaneous physical activity in obesity conditions could slow down tumour growth through crosstalk between muscle, adipose tissue and tumour. A spontaneous moderate physical activity was able to modify the inter-organ exchange in a paracrine manner. The different tissues changed their signalling pathways and adipokine/cytokine secretions, such as adiponectin and leptin, resulting in a decrease in anti-oxidative response and inflammation in the tumour environment. This model showed that moderate, spontaneous physical activity suppresses tumour growth via a dialogue between the organs close to the tumour.

9 July 2020 in BioEssays
Verified
Journal Article
Closed access
PDF file
MGMarie Goepp
Marie Goepp
DGDelphine Le Guennec
Delphine Le Guennec
ARADRIEN ROSSARY
ADRIEN ROSSARY
MVMarie‐Paule Vasson
Marie‐Paule Vasson

20 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMarie Goepp
Marie Goepp
SCSiobhan Crittenden
Siobhan Crittenden
YZYou Zhou
You Zhou
Adriano RossiAdriano Rossi
Adriano Rossi
SNShuh Narumiya
Shuh Narumiya
CYChengcan Yao
Chengcan Yao
Background and Purpose: Regulatory T (Treg) cells are essential for control of inflammatory processes by suppressing Th1 and Th17 cells. The bioactive lipid mediator prostaglandin E 2 (PGE 2 ) promotes inflammatory Th1 and Th17 cells and exacerbates T cell-mediated autoimmune diseases. However, the actions of PGE 2 on the development and function of Treg cells, particularly under inflammatory conditions, are debated. In this study, we examined whether PGE 2 had a direct action on T cells to modulate de novo differentiation of Treg cells. Experimental Approach: We employed an in vitro T cell culture system of TGF-β-dependent Treg induction from naïve T cells. PGE 2 and selective agonists for its receptors, and other small molecular inhibitors were used. Mice with specific lack of EP4 receptors in T cells were used to assess Treg cell differentiation in vivo . Human peripheral blood T cells from healthy individuals were used to induce differentiation of inducible Treg cells. Key Results: TGF-β-induced Foxp3 expression and Treg cell differentiation in vitro was markedly inhibited by PGE 2 , which was due to interrupting TGF-β signalling. EP2 or EP4 agonism mimicked suppression of Foxp3 expression in WT T cells, but not in T cells deficient in EP2 or EP4, respectively. Moreover, deficiency of EP4 in T cells impaired iTreg cell differentiation in vivo . PGE 2 also appeared to inhibit the conversion of human iTreg cells. Conclusion and Implications: Our results show a direct, negative regulation of iTreg cell differentiation by PGE 2 , highlighting the potential for selectively targeting the PGE 2 -EP2/EP4 pathway to control T cell-mediated inflammation. What is already known: PGE 2 promotes inflammatory Th1 and Th17 cells and facilitates T cell-mediated immune inflammation, but the action of PGE 2 on Treg cells is debated. What does this study add: PGE 2 directly acts on T cells to inhibit inducible Treg cell differentiation in vitro and in vivo through its receptors EP2 and EP4 and by antagonising TGF-β signalling. What is the clinical significance: Therapeutically blocking the EP4 receptor may be beneficial for management of T cell-mediated autoimmune inflammation.